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Background: Failure to account for the etiological diversity that typically occurs in psychi-
atric cohorts may increase the potential for confounding as a proportion of genetic variance
will be specific to exposures that have varying distributions in cases.This study investigated
whether minimizing the potential for such confounding strengthened the evidence for a
genetic candidate currently unsupported at the genome-wide level.
Methods: Two hundred and ninety-one first-episode psychosis cases from South Lon-
don, UK and 218 unaffected controls were evaluated for a functional polymorphism at the
rs1360780 locus in FKBP5. The relationship between FKBP5 and psychosis was modeled
using logistic regression. Cannabis use (Cannabis Experiences Questionnaire) and parental
separation (Childhood Experience of Care and Abuse Questionnaire) were included as
confounders in the analysis.
Results: Association at rs1360780 was not detected until the effects of the two environ-
mental factors had been adjusted for in the model (OR=2.81, 95% CI 1.23–6.43, p=0.02).
A statistical interaction between rs1360780 and parental separation was confirmed by
stratified tests (OR=2.8, p=0.02 vs. OR=0.89, p=0.80). The genetic main effect was
directionally consistent with findings in other (stress-related) clinical phenotypes. More-
over, the variation in effect magnitude was explained by the level of power associated with
different cannabis constructs used in the model (r =0.95).
Conclusion: Our results suggest that the extent to which genetic variants in FKBP5 can
influence susceptibility to psychosis may depend on other etiological factors. This find-
ing requires further validation in large independent cohorts. Potentially this work could
have translational implications; the ability to discriminate between genetic etiologies based
on a case-by-case understanding of previous environmental exposures would confer an
important clinical advantage that would benefit the delivery of personalizable treatment
strategies.
Keywords: FKBP5, psychosis, confounding factors, cannabis, childhood adversity, gene–environment, GWAS,
missing heritability
INTRODUCTION
The broad etiological basis of psychosis adds to the expectation
that the genetic pathways to the disorder will be similarly diverse.
But evidence in support of this theory has been hard to come
by in psychosis research. One reason for this is that exposures
which may have contributed to the clinical state are rarely docu-
mented in genetic research. Gene–environment interaction (GxE)
is the archetypal strategy for exploring interplay between genes
and environment (1, 2) but is not the only plausible mechanism
that may occur. For example, failing to account for diversity of the
etiological pathways to psychosis may be contributing to genetic
confounding, because a proportion of the genetic variance associ-
ated with the psychosis trait will be attached to exposures (such as
cannabis), which have a limited distribution in psychosis cohorts
(2, 3). Adding to this complexity is the fact that exposure to a risk
factor does not impact all members of a cohort equally.
In its present format, genome-wide association (GWA) is biased
toward the discovery of associations that are robust to these
concerns. In theory at least, one way the range of GWA vari-
ants for psychosis could be extended beyond this constraint is
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by incorporating the environmental structure of the cohort into
GWA analyses, as was recently attempted in depression (4). We
employ the term, “environmental stratification” to describe the
consequences of ignoring this problem, given that it may resemble
“population stratification,” a well-recognized phenomenon and
source of distortion in genetic studies. Social science has drawn
attention to additional higher order complexity in non-genetic
risk models for psychosis. For instance, several lines of evidence
suggest that interaction between childhood trauma and cannabis
smoking should be routinely tested and adjusted for in studies of
psychosis (5–7). However, in genetic studies it has not been proven
that the etiological composition of a cohort can impede the dis-
covery of underlying associations. One way in which the theory
can be tested is by examining the impact of correcting for such
structure on the detection of association signals.
With this in mind, we set out to test the credentials of
FKBP5 (FK506 binding protein 5) as a genetic risk factor for
psychosis. FKBP5 performs a vital physiological function at the
gene–environment interface, as it regulates the activity of the
hypothalamic–pituitary–adrenal axis (HPA) system. This regula-
tory function is known to be perturbed by genetic and epigenetic
events in some stress-related conditions (8–10). In particular, the
link between rs1360780 and psychiatric disorders is endorsed by
high-level functional research (9, 10) but it curiously lacks GWA
support in any one particular disorder. Two studies have already
looked at the possible relevance of FKBP5 to psychosis. Gawlik
et al. (11) tested for an association of rs1360780 with affective psy-
chosis, in a study that controlled for group differences in gender,
but did not model environmental co-factors. The study failed to
provide evidence in support of an association with psychosis. The
second, more recent study by Collip et al. (12) found limited evi-
dence of an interaction between FKBP5 and childhood trauma.
One explanation for this could be that the variable level of con-
trol for environmental effects exercised in the study limited the
ability to detect the interaction. Moreover, this study focused on
symptoms and did not explore full-blown psychotic disorder as an
outcome.
We therefore set out to test for a main effect of rs1360780 on
the presence of psychotic disorder. Our approach incorporates an
attempt to reduce environmental confounding and assess the con-
sequence this has on the genetic association. Specifically, we adjust
for cannabis use and childhood adversity, with the type of adver-
sity informed by the statistical power in the available sample. Both
factors are known to be associated with psychosis in the original
population from which the sample is drawn (3, 13, 14).
MATERIALS AND METHODS
RECRUITMENT
Patients (n= 291) aged 18–65 years and presenting with their
first-episode of psychosis to psychiatric inpatient wards in Lam-
beth, Southwark, and Croydon (South London, UK), between
December 2005 and April 2011 were invited to take part in the
study. All patients that met ICD-10 (15) criteria for non-organic
psychosis (codes F20–F29 and F30–F33) were considered eligi-
ble. Controls (n= 218) were drawn from the same geographical
areas as cases. All controls were asked to complete a Psychosis
Screening Questionnaire (PSQ) (16) in order to determine the
FIGURE 1 | Flow diagram and numerical breakdown of outcomes for
subject recruitment and genotyping.
possibility of having an undiagnosed psychotic disorder. Controls
who responded positively to items on the PSQ were excluded if
they were subsequently found to meet diagnostic criteria for a
psychotic disorder or reported a history of psychosis. Potential
cases and controls with severe learning disability (IQ< 50) or poor
English fluency were excluded. An overview of recruitment and
attrition can be found in Figure 1.
ETHICS
The study cohort used is drawn from the Genetics And Psychosis
(GAP) study, which was granted ethical approval by the South
London and Maudsley and Institute of Psychiatry Local Research
Ethics Committee (Ethics reference number: 05/Q0706/158). All
cases and controls gave informed written consent after reading a
detailed information sheet.
CANNABIS EXPERIENCES QUESTIONNAIRE
A simple yes/no question about life-time cannabis use was
included in the original GAP questionnaire in 2005. A more
detailed history of illicit drug use for each subject was introduced
when the modified version of the Cannabis Experiences Question-
naire was implemented in 2006 (17). Three primary measures of
cannabis use were used in the study: life-time cannabis use (never
vs. at least once), frequency of use (life-time, yearly, monthly,
weekly, or daily use), and type of cannabis used (hash-like or
skunk-like). The most important discrepancy between hash-like
and skunk-like forms of cannabis lies in the content of the psy-
choactive agent as Tetrahydrocannabinol (THC) content varies
from 4% in hash to 18% in skunk (3). The later introduction of
the detailed cannabis scale to the GAP study has repercussions for
Frontiers in Psychiatry | Schizophrenia July 2014 | Volume 5 | Article 84 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ajnakina et al. Environmental confounding of FKBP5 -psychosis association
sample size, which become apparent in analyzes that use detailed
cannabis measures. For example, the maximum available n for the
“frequency of use” measure was 234 in the subset of GAP with
available data on adversity in childhood, whereas for the “life-time
use” measure data on 455 was available in the same subset.
CHILDHOOD EXPERIENCE OF CARE AND ABUSE QUESTIONNAIRE
Childhood adversity was assessed using the Childhood Experi-
ence of Care and Abuse Questionnaire (CECA.Q) (18). This is a
self-report retrospective measure designed to capture traumatic
experiences occurring before the age of 17. Summary variables
were created for parental separation, physical, and sexual abuse
[see Fisher et al. (13) for full details]. The scales used to mea-
sure each variable were dichotomized using the most conservative
published cut-off points (18). This ensured that scores in the affir-
mative reflected a reasonable level of severity in the analysis and
is consistent with previous analyses conducted with this measure
(13, 18). The CECA.Q has previously been shown to be reliable in
patients with psychosis (19).
VALIDATION OF SELF-REPORTED ETHNICITY
Genetic ancestry was derived from a panel of 57 ancestry infor-
mative genetic markers. These were genotyped using iPLEX tech-
nology developed for the MassArray platform (Sequenom Inc.,
San Diego, CA, USA). Further information on the makeup of the
marker panel is available on request. Ancestry scores were derived
using the program Structure (20) to implement a model-based
(Markov Chain Monte Carlo) clustering algorithm. Further details
of the methodology used are described in a previous paper (21).
GENOTYPING
DNA material from buccal swabs and blood samples was obtained
from a total of 509 subjects (291 cases and 218 controls). DNA was
extracted using a standard phenol–chloroform extraction proce-
dure. A Taqman SNP assay (Applied Biosystems, USA) was used
to report the presence of either one or both alleles (C and T) at the
rs1360780 locus. Genotypic concordance was checked for a sub-
set of cases for which cheek swab and blood DNA was available
(n= 126). Concordance between the two sources was 100%.
STATISTICAL ANALYSIS
Power calculations were performed in Quanto, version 1.2.4 (Uni-
versity of Southern California, USA). All other analyses were con-
ducted using STATA, release 12 (STATACorp LP, USA). Genotypic
coding for the genetic analysis reflected either additivity (CC vs.
CT vs. TT) or dominance (CC vs. CT+TT). Chi-square tests were
used to identify variables confounded with either diagnostic status
or genotype. Logistic regression analyses incorporated these vari-
ables into a model that included age, gender, and genetic ancestry.
A single measure of childhood trauma was selected for use in these
analyses on the basis of statistical power, whereas three cannabis
measures (life-time use, cannabis type, and frequency of smok-
ing) were used in the analysis for comparison purposes. In this
study G× E interaction is defined as a departure from multiplica-
tivity, unless otherwise stated. Consideration of E× E effects was
prompted by three previous studies in this area (5–7). These stud-
ies all report interactions between cannabis smoking and child-
hood adversity that transcend differences between additive and
multiplicative scaling. The E× E model used considered effects
on a multiplicative interaction scale.
RESULTS
A total of 509 out of 524 possible genotypes were obtained. This
corresponds to an overall call rate of 97%. Allele frequencies
(for the rs1370780-T allele) were compared with HAPMAP ref-
erence populations (22). Allele frequencies deviated only slightly
from the expected proportions in Caucasians and Africans. Nei-
ther deviation was statistically significant (X2≤ 1.149; p≥ 0.41).
Genotypes were in the expected proportions, given allelic fre-
quency (X2= 0.12; p= 0.74). Therefore, no evidence of bias in
the derivation of genotypic data could be detected.
The proportion of male psychosis cases was significantly greater
compared to controls (60.1 vs. 50.5%, X2= 4.3; p= 0.04), but the
median age at assessment did not differ between the two groups
(27 vs. 26 years, Z= 0.006; p= 0.95). The comparison groups used
in this study were diverse in terms of the self-reported ethnic labels
used (Fisher’s Exact X2= 24.25; p= 0.001). For this reason, genetic
ancestry scores are used henceforth to index quantitative ancestry.
There was a high degree of correspondence between self-reported
ethnicity and mean ancestry scores (Table S1 in Supplementary
Materials). The main effects of genetic and non-genetic risk factors
on psychotic disorder are presented in Table 1.
Of the three measures of adversity shown in Table 1, only
parental separation was significantly associated with psychosis
after adjustment for sex, age, and genetic ancestry (ORadj= 1.96,
p= 0.001).
Although a higher proportion of cases admitted to having
used cannabis during their life-time (Table 1), this trend did not
reach significance at the 5% level (ORadj= 1.31, p= 0.19). How-
ever, daily cannabis use was significantly higher among cases than
controls (54.2 vs. 18.1%) compared to all other intake regimes
combined (ORadj= 5.86,p< 0.0001). There was also increased use
of THC-enriched “skunk-like” varieties of cannabis among cases
(78.6 vs. 47%; ORadj= 3.44, p< 0.0001). No main effect between
FKBP5 and psychotic disorder was observed in either crude or
adjusted models.
Overall, the profile of cannabis usage in this cohort concurs
with that of a larger, partially overlapping dataset (3). We found
no deviation in usage profile (frequency, type) from the larger
dataset from which this cohort was derived (frequency of use:
X2= 1.6, p= 0.8; cannabis type: X2= 2.8, p= 0.1). In summary,
the associations between parental separation, cannabis use, and
psychotic disorder in this sample are consistent with our previ-
ously published data (3, 14), on socio-environmental risk factors
for psychosis, thus, there is no evidence to suggest that sam-
pling bias has altered the characteristics of the sample used in
the analyses that follow.
ASSOCIATION BETWEEN FKBP5 AND ENVIRONMENTAL FACTORS
Table 2 shows the relationship between genotype at locus
rs1360780 and environmental risk factors in this sample. Out of
the three types of adversity and three cannabis measures initially
included, only parental separation shows evidence of associa-
tion with genotype, although the effect only borders statistical
significance (X2= 6.13, p= 0.05). Further group-specific analyses
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Table 1 | Main effects of environmental risk factors and FKBP5 on psychotic disorder.
Environmental variable Variant N Unaffected controls Psychosis cases Association with psychotic disorder
n (%) n (%) Unadjusted OR
(95% CI); p value
Adjusted* OR
(95% CI); p value
Separation from parent
before 17 (n=493)
No 261 138 (63.6) 123 (44.6) 2.17 (1.5–3.1); <0.0001 1.96 (1.3–2.9); 0.001
Yes 232 79 (36.4) 153 (55.4)
Physical abuse before 17
(n=496)
No 399 183 (84.3) 215 (77.3) 1.57 (0.99–2.49); 0.06 1.30 (0.8–2.12); 0.29
Yes 97 34 (15.7) 63 (22.7)
Sexual abuse before age
17 (n=496)
No 429 192 (88.5) 237 (85.0) 1.36 (0.80–2.31); 0.26 1.39 (0.79–2.46); 0.25
Yes 67 25 (11.5) 42 (15.0)
Life-time cannabis use
(n=455)
No 236 105 (56.5) 131 (48.7) 1.37 (0.94–1.99); 0.10 1.31 (0.87–1.96); 0.19
Yes 219 81 (43.5) 138 (51.3)
Frequency of cannabis
use (n=234)
Non-daily use 149 95 (82.0) 54 (45.8) 5.36 (2.95–9.72); <0.0001 5.86 (3.02–11.37); <0.0001
Daily Use 85 21 (18.0) 64 (54.2)
Type of cannabis use
(n=228)
Hash 84 59 (53.2) 25 (21.4) 4.16 (2.34–7.44); <0.0001 3.44 (1.87–6.32); <0.0001
Skunk 144 52 (46.9) 92 (78.6)
FKBP5 rs1360780
(n=509)
CC 214 96 (44.0) 118 (40.5) 1.19 (0.92–1.55); 0.18 1.10 (0.83–1.46); 0.5
CT 228 98 (45.0) 130 (44.7)
TT 67 24 (11.0) 43 (14.8)
*Adjusted for sex, age, and genetic ancestry. CI, confidence interval; OR, odds ratio.
suggest that the association is exclusive to cases (X2= 6.9, p= 0.03)
and not controls (X2= 1.06, p= 0.6); this implies G× E between
FKBP5 and parental separation, as opposed to gene–environment
correlation.
INTERACTION BETWEEN CANNABIS USE AND CHILDHOOD ADVERSITY
The need to account for interaction between life-time cannabis use
and childhood adversity in this sample (5–7) was assessed objec-
tively by attempting to replicate the interaction using chi-square
tests. However, we failed to find statistical support for the interac-
tion in the current dataset (Table S2 in Supplementary Materials;
p≥ 0.49; n≥ 420). Based on this result interactions between envi-
ronmental variables (E× E) were excluded from consideration in
the full logistic model applied in the next section.
EFFECT OF ADJUSTING FOR ENVIRONMENTAL EXPOSURE ON FKBP5
ASSOCIATION WITH PSYCHOTIC DISORDERS
The full logistic model we applied included terms for parental sep-
aration, cannabis use, sex, age, genetic ancestry, and the interaction
between FKBP5 and parental separation (see Table 2). The out-
comes of interest were the logistic regression statistics, which assess
the association between FKBP5 and psychotic disorder. Results are
presented in Table 3.
A trend effect found under the additive genetic model (Table 3,
model 2) was driven by the heterozygote (CT ) genotype class.
This was enough to prompt a recode of genotype data in order to
allow re-estimation of the same parameters under the dominance
genetic model (models 4–6). This had the added advantage of
addressing the statistical constraint imposed by the low representa-
tion of the TT genotype class (n= 67) (see Table 1). This recoding
brought main effects and interactions into sharper focus, especially
in model 5 (Table 3) where the main effect of FKBP5 was strongest
(OR= 2.81, p= 0.02). The direction of this effect accords with
previous studies in which the T allele mediates increased risk
(see Table S3 in Supplementary Materials). The interaction effect
peaks in model 5, and is directionally consistent across models
1–6. The T allele confers protection from risk in this interaction.
Overall, the inclusion of both main and interaction terms in the
model significantly benefits model-fit performance (Likelihood
Ratio Statistic= 6.12, ptwo-tailed= 0.047, df= 2).
The interaction was reinterpreted using the additive scale (23).
The interaction effect on psychosis caseness again proved to be sig-
nificant at the p< 0.05 level (data not shown). This suggests that
the significant interaction terms in Table 3 are not merely the con-
sequence of logarithmic scaling, as has previously been proposed
(24). The interaction result is therefore worthy of independent
replication efforts.
STRATIFIED TESTS
Table 3 suggests that a main effect of FKBP5 is obscured by
etiological heterogeneity within the sample. We sought further
clarification of the result from a stratified analysis. The importance
of parental separation to the genetic model can be confirmed by
the data shown in Table 4, which demonstrates the effect of the
locus on presence of psychotic disorder and its dependence on
exposure status.
GENETIC POWER OF THE CANNABIS VARIABLES
Table S4 in Supplementary Materials presents the power of
the three cannabis constructs used in these analyses. Genetic
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Table 2 | Association between environmental risk factors and FKBP5 genotype.
Environmental variable Variant N CC CT TT Genotypic association*
n (%) n (%) n (%) X2 (p value)
Physical abuse before age 17 No 408 168 (81.6) 179 (80.0) 52 (78.9) 0.44 (0.80)
Yes 100 38 (18.4) 45 (20.0) 14 (20.1)
Sexual abuse before age 17 No 203 79 (38.54) 106 (47.5) 18 (28.1) 2.19 (0.34)
Yes 289 126 (61.5) 117 (52.5) 46 (71.9)
Life-time cannabis use No 236 95 (50.53) 110 (53.92) 31 (49.21) 0.66 (0.72)
Yes 219 93 (49.47) 94 (46.08) 32 (50.79)
Frequency of cannabis use Low 149 61 (62.2) 69 (68.3) 19 (54.3) 2.85 (0.24)
High 85 37 (37.8) 32 (31.7) 16 (45.7)
Type of cannabis use Hash-like 84 36 (35.3) 37 (37.4) 11 (40.7) 0.29 (0.86)
Skunk-like 144 66 (64.7) 62 (62.6) 16 (59.3)
Separation from either parent before 17 No 261 106 (51.5) 129 (57.8) 26 (40.6) 6.13 (0.05)
Yes 232 100 (48.5) 94 (42.2) 38 (59.4)
Separation from parent before 17 (CONTROLS) No 138 62 (65.2) 63 (64.29) 13 (54.17) 1.06 (0.59)
Yes 79 33 (34.74) 35 (35.71) 11 (45.83)
Separation from parent before 17 (CASES) No 123 44 (41.53) 66 (51.94) 13 (31.71) 6.9 (0.03)
Yes 153 67 (58.47) 59 (48.06) 27 (68.29)
*Calculated under an assumed additive genotypic model using a 3×2 (2df) chi-square test.
Table 3 | Effect of FKBP5 on psychosis caseness after adjusting for environmental exposures.
Genetic model Model no. Basic model*, plus n Rs1360780
Main effect; OR (95% CI); Interaction effect; OR (95% CI);
p value p value
Additive 1 Life-time cannabis use 420 1.29 (0.89–1.87); 0.18 0.57 (0.26–1.25); 0.16
2 Frequency of cannabis use 227 1.63 (0.96–2.77); 0.07 0.47 (0.16–1.41); 0.18
3 Type of cannabis used 220 1.54 (0.87–2.7); 0.14 0.39 (0.13–1.20); 0.10
Dominant 4 Life-time cannabis use 420 1.54 (0.90–2.93); 0.11 0.51 (0.22–1.17); 0.11
5 Frequency of cannabis use 227 2.81 (1.23–6.43); 0.02 0.31 (0.09–1.04); 0.06
6 Type of cannabis used 220 2.02 (0.89–4.65); 0.10 0.34 (0.08–1.04); 0.07
Models 1–6 vary in terms of (i) which cannabis variables are modeled and (ii) the genetic effect model applied (i.e., additivity vs. dominance).
*Basic model: parental separation, genetic ancestry, sex, age, the main effect of rs1360780, and the SNP× separation G×E term.
(CI, confidence interval; OR, odds ratio).
power to detect the genetic main effects shown in Table 3
does not so much depend on sample size (r =−0.78) as it
does on the power of the cannabis construct used (r = 0.95)
(Table S5 in Supplementary Materials). This is also illustrated
in Figure 2. Hence, genetic power is maximized when “fre-
quency of cannabis use” is included in the covariate model
and is weakest when the measure is substituted with “life-
time cannabis use.” This dosage effect of non-genetic power
on genetic outcomes seems to be consistent with our hypoth-
esis that the environmental effects may need to be attenuated
in order to demonstrate associations between rs1360780 and
psychosis.
DISCUSSION
This study attempted to investigate whether the etiological hetero-
geneity typically found in large clinical cohorts is a root cause of the
uncertainty regarding FKBP5’s relevance to psychosis. This uncer-
tainty includes a lack of GWA support and the mixed performance
of the target locus in one recent study (12). Our approach to over-
coming the heterogeneity“problem”involved an analytical process
in which terms for environmental exposure were incorporated into
a logistic regression model. An association between rs1360780 and
psychosis was not detected until cannabis use and parental sepa-
ration had been adjusted for in the analysis (OR= 2.81, p= 0.02).
The genetic main effect found is directionally consistent with
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Table 4 | Stratification of association between FKBP5 and psychotic
disorder by parental separation.
Parental separation Adjusted effect of rs1360780;
OR (95% CI), p value
Yes (n=114) 0.89 (0.37–2.17), 0.80
No (n=114) 2.8 (1.21–6.60), 0.02
Genetic terms used in the analysis are dominance-coded and *adjusted for sex,
age, genetic ancestry, and frequency of cannabis use.The partitioning of parental
separation in this stratified analysis makes the G×E term used in the logistic
model (FKBP5×parental separation) redundant in this analysis. CI, confidence
interval; OR, odds ratio.
FIGURE 2 | Environmental vs. genetic power in the conditioned
analyses of association with psychotic disorder. Life-time cannabis use,
cannabis type, and frequency of cannabis use are associated with low
(23%), intermediate (68%), and high (98%) statistical power (respectively)
(Table S5 in Supplementary Materials). These power analyses confirm that
conditioning on the more discriminating measures of cannabis use leads to
larger genetic effects and, correspondingly, better detection efficiency
(genetic power). The same pattern was also seen when these analyses
were repeated under an additive genetic model.
that of the same locus in other (stress-related) clinical pheno-
types (8–10). Moreover, we have found that the magnitude of the
effect varies with the power of the different cannabis-related mea-
sures included in the model (r = 0.95). The statistical interaction
between rs1360780 and parental separation was confirmed in a
stratified analysis (OR= 2.8, p= 0.02 vs. OR= 0.89, p= 0.80).
One interpretation of the findings described is that they repre-
sent evidence of a genetic delineation between different etiological
pathways to psychosis. This would suggest a need to acknowledge
and understand the role of the environment in shaping and resolv-
ing genetic liability to mental illness including psychosis (25).
Advances such as the polygenic risk score, make this prospect more
feasible than ever (26, 27). The example of FKBP5 potentially
demonstrates that greater variety and subtlety of signal detec-
tion could be achieved (and hence, the interests of translational
medicine best served) if our awareness of non-genetic risk factors
is harnessed in the discovery process. Failure to accomplish this
may come at the expense of the translational goals of psychiatric
research (28, 29) as “missing heritability” is a complex void which
genome only approaches are unlikely to explain in full, irrespective
of ever improving sample sizes (30). This is because the etiological
complexity we have outlined (and its potentially negative impact
on signal detection) does not diminish with scale.
There are important contrasts to consider between our results
and those of a previous study of psychosis focused on the same SNP
(12). Firstly, the studies differ with respect to the types of effect
sought: the effect of interest in Collip et al. (12) was a G× E inter-
action involving the rs1360780 locus and a much broader trauma
definition than was used here, while the focus of the present study
was primarily genetic main effects. Moreover, they focused specif-
ically on psychotic symptoms whereas our outcome was presence
of a clinically relevant psychotic disorder. However, we did find
evidence of an interaction between FKBP5 and parental sepa-
ration. Therefore, the two studies are consistent in this regard,
although specific effects on risk appear to be discrepant between
the studies.
Despite the different hypothesis explored by each study (i.e.,
main effects vs. interaction), the theory of environmental con-
founding could explain why interactions mediated in the vicinity
of rs1360780 showed poor consistency in the analyses of Collip
et al (12). In the dominance models of Table 3, interaction effects
are as dependent on the power of cannabis measures as main
effects (Table S4 in Supplementary Materials and Figure 2). Thus,
the interaction is under strong potentiation when “frequency of
cannabis use” is included with “parental separation” in the con-
founder model (Table 3: OR= 0.31, p= 0.06). This trend also
seems to be reflected in the results of Collip et al. (12): in their
first two analyses, which control for stressful life events (models
1 and 2), interaction effects range from suggestive to significant
(p< 0.08). In models 3, 4, and 5, statistical evidence of interaction
is generally weaker (p> 0.1), this is seemingly because adjustment
for the confounding effect of stressful life events was not imple-
mented in this set of analyses. In total, Collip et al. (12) conducted
five separate analyses, spanning sub-clinical and biological expres-
sions of psychosis-related traits. Two variants in close genetic
proximity to rs1360780 (r ≥ 0.80) were found to be the most
consistent across all five models. Our own analytical design addi-
tionally factors-in cannabis-related characteristics of the cohort
while cannabis does not feature in the models of Collip et al. (12).
However, as an important risk factor for psychosis (3) that also
influences the sub-clinical expressions of this trait (31, 32), we
suggest it is appropriate to adjust for its potentially confounding
effects.
This study has a number of methodological limitations that
should be taken into account when interpreting these findings. We
were unable to control for symptoms of depression in our cohort,
because such data was not collected. Previously reported main and
interaction effects of rs1360780 span the depression phenotype (9,
33, 34), therefore, a failure to control for this as a further possi-
ble confounder is a limitation of this study. Another limitation is
the likelihood that effects in this sample (and hence, our power to
detect them) are overestimated, due to the relatively small sample
used. Hence, larger cohorts are required to validate these findings.
Additionally, the p values reported in this study have not been
corrected for multiple-testing. The reasons for this are twofold:
(i) a balanced penalization strategy should take into account the
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compelling evidence that made rs1360780 our preferred genetic
candidate (e.g., 8–10, 33, 34); and (ii) the bulk of the additional
testing relates to the formulation of our environmental model. For
this we applied a principled approach, which sought to identify and
use the most statistically relevant adverse childhood exposure in
the cohort. We then explored the relationship between power and
genetic outcome across all three cannabis measures. Finally, the
study has been performed on a restricted (hospitalized) patient
population within an inner-city area and controls were not ran-
domly selected, though they were broadly matched across several
demographic criteria (age, education, and ethnicity). This may
limit the generalizability of the findings. Future work could include
further evaluation of our findings in more representative psychosis
samples and community-based populations.
CONCLUSION
Although, we were able to detect the hypothesized effect of FKBP5
on presence of psychotic disorder, the fact that our ability to
detect this signal depended on controlling for environmental
exposures suggests that FKBP5’s contribution may vary depend-
ing on the etiology relevant to each case. Translation of these
findings into clinical practice might one day serve the need to
factor individual profiles of exposure into calculations of per-
sonal risk. The ability to accurately pinpoint or discriminate the
relevant genetic etiology based on a case-by-case understanding
of environmental pathology, could provide an important clini-
cal advantage by strengthening personalized medicine approaches
within psychiatry.
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